OverviewSuggest Edit

Stealth BioTherapeutics is a biopharmaceutical company developing therapies to treat mitochondrial dysfunction associated with genetic mitochondrial diseases and common diseases of aging. The Company's team works with patients and advocacy organizations to better understand their health problems and raise awareness of the rare genetic diseases. 

TypePublic
Founded2007
HQNewton, MA, US
Websitestealthbt.com

Latest Updates

Employees (est.) (Feb 2019)59(-1%)
Revenue (FY, 2019)$21.1 M
Share Price (Jun 2021)$1.6(-3%)

Key People/Management at Stealth BioTherapeutics

Reenie McCarthy

Reenie McCarthy

CEO, Executive Director
Brian Blakey

Brian Blakey

Chief Business Officer
Jim Carr

Jim Carr

Chief Clinical Development Officer
Marty Redmon

Marty Redmon

Chief Research & Development Officer
Rob Weiskopf

Rob Weiskopf

Chief Financial Officer
Henry Hess

Henry Hess

Chief Legal Counsel
Show more

Stealth BioTherapeutics Office Locations

Stealth BioTherapeutics has offices in Newton and Needham
Newton, MA, US (HQ)
Riverside Center, 275 Grove St #3, Auburndale
Needham, MA, US
140 Kendrick St building c, Needham Heights
Show all (2)

Stealth BioTherapeutics Financials and Metrics

Stealth BioTherapeutics Revenue

Stealth BioTherapeutics's revenue was reported to be $21.09 m in FY, 2019
USD

Revenue (FY, 2019)

21.1m

Net income (FY, 2019)

(71.7m)

EBIT (FY, 2019)

(45.8m)

Market capitalization (11-Jun-2021)

89.0m

Closing stock price (11-Jun-2021)

1.6

Cash (31-Dec-2019)

50.8m

EV

55.7m
Stealth BioTherapeutics's current market capitalization is $89 m.
USDFY, 2016FY, 2017FY, 2018FY, 2019

Revenue

21.1m

General and administrative expense

13.4m16.5m22.2m22.3m

R&D expense

48.4m63.2m53.1m44.6m

Operating expense total

61.8m79.7m75.3m66.9m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Cash

9.7m4.1m10.9m50.8m

Prepaid Expenses

1.7m1.8m2.4m1.6m

Current Assets

13.3m52.4m

PP&E

999.5k795.9k498.6k345.0k
Quarterly
USDQ3, 2018

Cash

4.1m

Prepaid Expenses

951.8k

PP&E

572.5k

Total Assets

11.6m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(61.0m)(82.9m)(96.7m)(71.7m)

Depreciation and Amortization

312.5k346.9k309.0k584.0k

Accounts Payable

767.8k4.5m3.6m(1.5m)

Cash From Operating Activities

(54.0m)(69.8m)(72.1m)(48.0m)
Quarterly
USDQ3, 2017Q3, 2018

Net Income

(60.8m)(70.1m)

Depreciation and Amortization

262.1k235.1k

Accounts Payable

1.7m1.4m

Cash From Operating Activities

(51.4m)(50.9m)
USDFY, 2016

Financial Leverage

8.6 x
Show all financial metrics

Stealth BioTherapeutics Acquisitions / Subsidiaries

Company NameDateDeal Size
Stealth BioTherapeutics
Stealth BioTherapeutics (HK) Limited
Stealth BioTherapeutics (Shanghai) Limited

Stealth BioTherapeutics Online and Social Media Presence

Embed Graph

Stealth BioTherapeutics News and Updates

Thinking about buying stock in Stealth BioTherapeutics, BlackBerry, Ideanomics, Seelos Therapeutics, or Altimmune?

NEW YORK, June 2, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MITO, BB, IDEX, SEEL, and ALT. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Stealth BioTherapeutics to Present at Jefferies Virtual Healthcare Conference

BOSTON, May 28, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that Reenie McCarthy,...

Stealth BioTherapeutics Announces Poster Presentation at American College of Cardiology (ACC) Annual Meeting

BOSTON, May 17, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that the company is...

Stealth BioTherapeutics CEO to Give Keynote Presentation at Mitochondria-Targeted Drug Development Summit

BOSTON, April 26, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that Reenie...

Stealth BioTherapeutics Reports Fiscal Year 2020 Financial Results And Recent Business Highlights

BOSTON, April 6, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today reported financial results for...

Stealth BioTherapeutics Announces Promotion of Marty Redmon to Chief Research & Development Officer

BOSTON, March 16, 2021 /PRNewswire/ -- Stealth BioTherapeutics (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced promotion of Marty Redmon,...
Show more

Stealth BioTherapeutics Blogs

People with Mitochondrial Disease Have Significant Medical Costs

A recent study published in Orphanet Journal of Rare Diseases reported that people with mitochondrial disease (mito) have significant medical costs, higher than that of the general population, and similar to a person with multiple sclerosis (MS) or amyotrophic lateral sclerosis (ALS). Download the i…

Stealth BioTherapeutics Granted Fast Track Designation for Elamipretide for the Treatment of Dry Age-Related Macular Degeneration with Geographic Atrophy

BOSTON – December 10, 2018 – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing therapeutics to treat mitochondrial dysfunction, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its lead investigational cand…

What is Barth Syndrome?

Barth syndrome is a rare, genetic, mitochondrial disorder causing metabolic abnormalities that can lead to an enlarged and weakened heart (cardiomyopathy), muscle weakness and fatigue (skeletal muscle myopathy), low levels of certain white blood cells that can lead to recurrent infections (neutropen…

Stealth BioTherapeutics Expands Pipeline, Advances New Compound

Stealth BioTherapeutics accelerates the development of a new pipeline candidate into Investigational New Drug enabling studies by leveraging Evotec’s INDiGO platform BOSTON – August 14, 2018 – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing a first-in-class p…

Stealth BioTherapeutics Announces $100m Financings to Advance Clinical Development of Elamipretide and Pipeline

BOSTON – June 18, 2018 – Stealth BioTherapeutics, a clinical-stage biopharmaceutical company developing a first-in-class platform of novel therapeutic compounds for the treatment of mitochondrial dysfunction, today announced the closing of an aggregate $100 million of financing in two convertible no…

The Journey to Diagnosis for People with Mitochondrial Disease

A recent study published in Neurology: Genetics documented the complex journey to diagnosis for people with rare mitochondrial diseases. The post The Journey to Diagnosis for People with Mitochondrial Disease appeared first on Stealth BioTherapeutics.

Stealth BioTherapeutics Frequently Asked Questions

  • When was Stealth BioTherapeutics founded?

    Stealth BioTherapeutics was founded in 2007.

  • Who are Stealth BioTherapeutics key executives?

    Stealth BioTherapeutics's key executives are Reenie McCarthy, Brian Blakey and Jim Carr.

  • How many employees does Stealth BioTherapeutics have?

    Stealth BioTherapeutics has 59 employees.

  • What is Stealth BioTherapeutics revenue?

    Latest Stealth BioTherapeutics annual revenue is $21.1 m.

  • What is Stealth BioTherapeutics revenue per employee?

    Latest Stealth BioTherapeutics revenue per employee is $357.4 k.

  • Who are Stealth BioTherapeutics competitors?

    Competitors of Stealth BioTherapeutics include Affinia Therapeutics, AID Genomics and Oxford BioTherapeutics.

  • Where is Stealth BioTherapeutics headquarters?

    Stealth BioTherapeutics headquarters is located at Riverside Center, 275 Grove St #3, Auburndale, Newton.

  • Where are Stealth BioTherapeutics offices?

    Stealth BioTherapeutics has offices in Newton and Needham.

  • How many offices does Stealth BioTherapeutics have?

    Stealth BioTherapeutics has 2 offices.